3Q22

3Q22

• 3Q22 Earnings Release

  • Elected the most amazing pharmaceutical company to work for by FIA/USP and UOL
  • Net Revenue recorded 19.5% growth in 3Q22, raising the accumulated growth in 9M22 to 13.2%, reaching R$ 718.3 million
  • Gross margin reaches 52.3% in 3Q22 with 50.6% accumulated margin in 9M22, amounting to R$ 363.2 million in gross profit
  • EBITDA reaches R$ 137.5 million with 9.3% growth
  • Leverage at 1.3x EBITDA, with 75% of debt via FINEP and BNDES